153 related articles for article (PubMed ID: 30172241)
1. Somatic TP53 Mutations Are Detectable in Circulating Tumor DNA from Children with Anaplastic Wilms Tumors.
Treger TD; Chagtai T; Butcher R; Cresswell GD; Al-Saadi R; Brok J; Williams RD; Roberts C; Luscombe NM; Pritchard Jones K; Mifsud W
Transl Oncol; 2018 Dec; 11(6):1301-1306. PubMed ID: 30172241
[TBL] [Abstract][Full Text] [Related]
2. TP53 mutational status is a potential marker for risk stratification in Wilms tumour with diffuse anaplasia.
Maschietto M; Williams RD; Chagtai T; Popov SD; Sebire NJ; Vujanic G; Perlman E; Anderson JR; Grundy P; Dome JS; Pritchard-Jones K
PLoS One; 2014; 9(10):e109924. PubMed ID: 25313908
[TBL] [Abstract][Full Text] [Related]
3. Droplet digital PCR for detection and quantification of circulating tumor DNA in plasma of head and neck cancer patients.
van Ginkel JH; Huibers MMH; van Es RJJ; de Bree R; Willems SM
BMC Cancer; 2017 Jun; 17(1):428. PubMed ID: 28629339
[TBL] [Abstract][Full Text] [Related]
4. Characteristics and outcomes of preoperatively treated patients with anaplastic Wilms tumors registered in the UK SIOP-WT-2001 and IMPORT study cohorts (2002-2020).
Vujanić GM; Mifsud W; Chowdhury T; Al-Saadi R; Pritchard-Jones K;
Cancer; 2022 Apr; 128(8):1666-1675. PubMed ID: 35119702
[TBL] [Abstract][Full Text] [Related]
5. Significance of TP53 Mutation in Wilms Tumors with Diffuse Anaplasia: A Report from the Children's Oncology Group.
Ooms AH; Gadd S; Gerhard DS; Smith MA; Guidry Auvil JM; Meerzaman D; Chen QR; Hsu CH; Yan C; Nguyen C; Hu Y; Ma Y; Zong Z; Mungall AJ; Moore RA; Marra MA; Huff V; Dome JS; Chi YY; Tian J; Geller JI; Mullighan CG; Ma J; Wheeler DA; Hampton OA; Walz AL; van den Heuvel-Eibrink MM; de Krijger RR; Ross N; Gastier-Foster JM; Perlman EJ
Clin Cancer Res; 2016 Nov; 22(22):5582-5591. PubMed ID: 27702824
[TBL] [Abstract][Full Text] [Related]
6. Detecting Circulating Tumor DNA in Hepatocellular Carcinoma Patients Using Droplet Digital PCR Is Feasible and Reflects Intratumoral Heterogeneity.
Huang A; Zhang X; Zhou SL; Cao Y; Huang XW; Fan J; Yang XR; Zhou J
J Cancer; 2016; 7(13):1907-1914. PubMed ID: 27698932
[TBL] [Abstract][Full Text] [Related]
7. TP53 alterations in Wilms tumour represent progression events with strong intratumour heterogeneity that are closely linked but not limited to anaplasia.
Wegert J; Vokuhl C; Ziegler B; Ernestus K; Leuschner I; Furtwängler R; Graf N; Gessler M
J Pathol Clin Res; 2017 Oct; 3(4):234-248. PubMed ID: 29085664
[TBL] [Abstract][Full Text] [Related]
8. Circulating tumor DNA as a prognostic marker in high-risk endometrial cancer.
Feng W; Jia N; Jiao H; Chen J; Chen Y; Zhang Y; Zhu M; Zhu C; Shen L; Long W
J Transl Med; 2021 Feb; 19(1):51. PubMed ID: 33536036
[TBL] [Abstract][Full Text] [Related]
9. Assessments of TP53 and CTNNB1 gene hotspot mutations in circulating tumour DNA of hepatitis B virus-induced hepatocellular carcinoma.
Kumar S; Nadda N; Quadri A; Kumar R; Paul S; Tanwar P; Gamanagatti S; Dash NR; Saraya A; Shalimar ; Nayak B
Front Genet; 2023; 14():1235260. PubMed ID: 37593116
[No Abstract] [Full Text] [Related]
10. Somatic mutation detection using various targeted detection assays in paired samples of circulating tumor DNA, primary tumor and metastases from patients undergoing resection of colorectal liver metastases.
Beije N; Helmijr JC; Weerts MJA; Beaufort CM; Wiggin M; Marziali A; Verhoef C; Sleijfer S; Jansen MPHM; Martens JWM
Mol Oncol; 2016 Dec; 10(10):1575-1584. PubMed ID: 28949453
[TBL] [Abstract][Full Text] [Related]
11. Targeted next generation sequencing of circulating tumor DNA provides prognostic information for management in breast cancer patients.
Shim H; Kwon MJ; Park IH; Kim MK; Cho EH; Lee J; Lee ST; Sim SH; Lee KS; Kim YH; Kim SK; Lee ES; Kong SY
Ann Transl Med; 2022 Jan; 10(2):28. PubMed ID: 35282050
[TBL] [Abstract][Full Text] [Related]
12. Prospective study of the efficacy and utility of TP53 mutations in circulating tumor DNA as a non-invasive biomarker of treatment response monitoring in patients with high-grade serous ovarian carcinoma.
Kim YM; Lee SW; Lee YJ; Lee HY; Lee JE; Choi EK
J Gynecol Oncol; 2019 May; 30(3):e32. PubMed ID: 30887755
[TBL] [Abstract][Full Text] [Related]
13. Exploratory Analysis of TP53 Mutations in Circulating Tumour DNA as Biomarkers of Treatment Response for Patients with Relapsed High-Grade Serous Ovarian Carcinoma: A Retrospective Study.
Parkinson CA; Gale D; Piskorz AM; Biggs H; Hodgkin C; Addley H; Freeman S; Moyle P; Sala E; Sayal K; Hosking K; Gounaris I; Jimenez-Linan M; Earl HM; Qian W; Rosenfeld N; Brenton JD
PLoS Med; 2016 Dec; 13(12):e1002198. PubMed ID: 27997533
[TBL] [Abstract][Full Text] [Related]
14. Circulating tumor DNA correlates with microvascular invasion and predicts tumor recurrence of hepatocellular carcinoma.
Wang J; Huang A; Wang YP; Yin Y; Fu PY; Zhang X; Zhou J
Ann Transl Med; 2020 Mar; 8(5):237. PubMed ID: 32309384
[TBL] [Abstract][Full Text] [Related]
15. Patient-Specific Circulating Tumor DNA Detection during Neoadjuvant Chemotherapy in Triple-Negative Breast Cancer.
Riva F; Bidard FC; Houy A; Saliou A; Madic J; Rampanou A; Hego C; Milder M; Cottu P; Sablin MP; Vincent-Salomon A; Lantz O; Stern MH; Proudhon C; Pierga JY
Clin Chem; 2017 Mar; 63(3):691-699. PubMed ID: 28073896
[TBL] [Abstract][Full Text] [Related]
16. TP53 mutation and MET amplification in circulating tumor DNA analysis predict disease progression in patients with advanced gastric cancer.
Li J; Li Z; Ding Y; Xu Y; Zhu X; Cao N; Huang C; Qin M; Liu F; Zhao A
PeerJ; 2021; 9():e11146. PubMed ID: 33959414
[TBL] [Abstract][Full Text] [Related]
17. FOXL2 and TERT promoter mutation detection in circulating tumor DNA of adult granulosa cell tumors as biomarker for disease monitoring.
Groeneweg JW; Roze JF; Peters EDJ; Sereno F; Brink AGJ; Paijens ST; Nijman HW; van Meurs HS; van Lonkhuijzen LRCW; Piek JMJ; Lok CAR; Monroe GR; van Haaften GW; Zweemer RP
Gynecol Oncol; 2021 Aug; 162(2):413-420. PubMed ID: 34083028
[TBL] [Abstract][Full Text] [Related]
18. Monitoring melanoma recurrence with circulating tumor DNA: a proof of concept from three case studies.
McEvoy AC; Pereira MR; Reid A; Pearce R; Cowell L; Al-Ogaili Z; Khattak MA; Millward M; Meniawy TM; Gray ES; Ziman M
Oncotarget; 2019 Jan; 10(2):113-122. PubMed ID: 30719207
[TBL] [Abstract][Full Text] [Related]
19. Evaluation of Circulating Tumor DNA in Patients with Ovarian Cancer Harboring Somatic PIK3CA or KRAS Mutations.
Ogasawara A; Hihara T; Shintani D; Yabuno A; Ikeda Y; Tai K; Fujiwara K; Watanabe K; Hasegawa K
Cancer Res Treat; 2020 Oct; 52(4):1219-1228. PubMed ID: 32599986
[TBL] [Abstract][Full Text] [Related]
20. Potential Clinical Utility of a Targeted Circulating Tumor DNA Assay in Esophageal Adenocarcinoma.
Cabalag CS; Yates M; Corrales MB; Yeh P; Wong SQ; Zhang BZ; Fujihara KM; Chong L; Hii MW; Dawson SJ; Phillips WA; Duong CP; Clemons NJ
Ann Surg; 2022 Aug; 276(2):e120-e126. PubMed ID: 35737908
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]